covid-19 treatment

Showing 15 posts of 15 posts found.

GSK building

EMA begin review of GSK & Vir COVID-19 treatment

May 10, 2021
Sales and Marketing COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir

The EMA has begun a rolling review of GSK and Vir’s sotrovimab treatment for COVID-19, which will continue until there …

Celltrion’s COVID-19 treatment shows promise against South African variant

April 30, 2021
Medical Communications COVID-19, celltrion, covid 19 news, covid-19 news, covid-19 treatment, pharma, pharma news

Celltrion’s regdanvimab treatment for COVID-19 has shown itself to be effective against the South African variant of the virus, according …

Jubilant’s oral remdesivir formulation shows positive results in human trial

April 22, 2021
COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir

Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …

Adagio raises $336 million to advance COVID-19 antibody

April 20, 2021
Manufacturing and Production Adagio, COVID-19, Financing, covid-19 treatment, pharma, pharma news

Adagio Therapeutics has financed $336 million to support the rapid advancement of their novel ADG20 antibody for the treatment and …

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

April 19, 2021
Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

Merck cease development of $425 million COVID-19 treatment

April 16, 2021
Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news

Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.

EMA to begin review of GSK and Vir’s COVID-19 treatment

April 16, 2021
Medical Communications COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir

The EMA have begun a review of GSK and Vir Biotechnology’s investigational COVID-19 antibody (VIR-7831) for patients at high risk …

AstraZeneca sign

AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19

April 13, 2021
Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news

AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …

Regeneron’s drug cocktail shown to prevent symptomatic COVID-19

April 13, 2021
Manufacturing and Production COVID-19, REGEN-COV, Regeneron, covid-19 treatment, pharma, pharma news

Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …

GSK building

GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial

March 29, 2021
Sales and Marketing COVID-19, GSK, Phase III trial, covid-19 treatment, vir

GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …

Merck and UCLA find new COVID-19 treatment candidate

March 25, 2021
COVID-19, Merck, berzosertib, covid-19 treatment, ucla

Merck (MSD in the UK), the UCLA, and other universities from the US and Germany have uncovered a compound that …

Roche’s drug cocktail reduces hospitalisation due to COVID-19 in Phase III trial

March 24, 2021
Research and Development COVID-19, Roche, covid-19 treatment

Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …

Kintor’s COVID-19 treatment reduces mortality by 92%

March 12, 2021
Medical Communications Brazil, Brazil variant, COVID-19, Kintor, covid-19 treatment

Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by 92%, in a clinical trial …

Eli Lilly building

Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial

March 11, 2021
COVID-19, Eli Lilly, covid-19 treatment

Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …

GSK building

GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s

February 26, 2021
Medical Communications COVID-19, GSK, coronavirus, covid-19 treatment, otilimab

GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has shown promising results in older …

Latest content